tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Exelixis (EXEL)
NASDAQ:EXEL
US Market
EXEL
Exelixis
RESEARCH TOOLSreports

Exelixis (EXEL) Stock News & Sentiment

Compare
3,139 Followers
Exelixis: Advancing Zanzalintinib Pipeline Underpins Buy Rating and $52 Target on Multi-Tumor Commercial Potential
Premium
Ratings
Exelixis: Advancing Zanzalintinib Pipeline Underpins Buy Rating and $52 Target on Multi-Tumor Commercial Potential
3d ago
EXEL
Exelixis and Merck Advance LITESPARK-033: A New Kidney Cancer Combo With High-Stakes Market Potential
Premium
Company Announcements
Exelixis and Merck Advance LITESPARK-033: A New Kidney Cancer Combo With High-Stakes Market Potential
2M ago
EXEL
Exelixis’s Strategic Oncology Expansion and Pipeline Innovations Justify Buy Rating
Premium
Ratings
Exelixis’s Strategic Oncology Expansion and Pipeline Innovations Justify Buy Rating
2M ago
EXEL
Exelixis’s Oncology Potential: A Buy Rating Amid Evolving mCRC Treatment Landscape and Unmet Needs
Premium
Ratings
Exelixis’s Oncology Potential: A Buy Rating Amid Evolving mCRC Treatment Landscape and Unmet Needs
2M ago
EXEL
Exelixis Announces Leadership Transition with New General Counsel
Premium
Company Announcements
Exelixis Announces Leadership Transition with New General Counsel
3M ago
8K
EXEL
Exelixis’ Earnings Call: Strong Growth Amid Challenges
Premium
Company Announcements
Exelixis’ Earnings Call: Strong Growth Amid Challenges
3M ago
EXEL
Exelixis’s Strong Financial Performance and Growth Prospects Earns Buy Rating from Yaron Werber
Premium
Ratings
Exelixis’s Strong Financial Performance and Growth Prospects Earns Buy Rating from Yaron Werber
3M ago
EXEL
More EXEL News >

EXEL News on the Web

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
Zacks
Bullish
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy?
Zacks
Bullish
Barclays Raises Price Target for Exelixis (EXEL) to $44 | EXEL Stock News
GuruFocus News
Bullish
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?
Zacks
Bullish
Exelixis price target raised to $44 from $41 at Barclays
TipRanks News
Bullish
Barclays Sticks to Its Hold Rating for Exelixis (EXEL)
TipRanks News
Neutral
EXEL: Morgan Stanley Maintains Rating, Raises Price Target | EXEL Stock News
GuruFocus News
Bullish
Exelixis (EXEL) Sees Progress in Drug Review for Colorectal Cancer Treatment
GuruFocus News
Bullish

News Score - Last 7 Days

Very Positive
EXEL
Sector Average
Media Buzz
This Week8 articles
Weekly Average5.75 articles
News Sentiment
This Week100%
Sector Average75%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is EXEL’s Media Buzz Sentiment?
8 articles about EXEL were published this week. In an average week, 5.75 articles are published.
    What is EXEL’s weekly average amount of articles?
    In an average week, 5.75 articles about EXEL are published.
      What is EXEL’s News Sentiment?
      100% of articles about EXEL were positive this week, compared to its sector average of 75%.
        Healthcare Stocks that are Trending in the News
        TECHBio-Techne
        MMSIMerit Medical Systems
        DVADaVita
        ALGNAlign Tech
        STARStrides Pharma Science Ltd
        Showing the stocks with the most bullish news sentiment over the past week